Overview Dividends

(CORT) Corcept Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2183521028

Korlym, Relacorilant, Dazucorilant, Miricorilant

Pharmaceuticals
Market Cap in USD: 4,025m

IPO / Inception: 2004-04-14
Return 12m vs S&P 500: -37.8%

EPS (Earnings per Share)

EPS CAGR: -44.34%
EPS Trend: -16.5%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 21.90%
Rev. Trend: 96.6%

Last SUE: -0.91
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	88.1%
Value at Risk 5%th	106%
Relative Tail Risk	-27.18%

Reward TTM
Sharpe Ratio	0.26
Alpha	-50.73
CAGR/Max DD	0.27

Character TTM
Hurst Exponent	0.606
Beta	1.303
Beta Downside	1.246

Drawdowns 3y
Max DD	69.53%
Mean DD	18.59%
Median DD	16.63%

Description: CORT Corcept Therapeutics January 06, 2026

Corcept Therapeutics (NASDAQ:CORT) is a U.S.-based biopharma that discovers and develops drugs for severe endocrine, oncologic, metabolic, and neurologic disorders, with its commercial focus currently on Korlym, a tablet approved to treat hyperglycemia secondary to hypercortisolism in adult Cushing’s syndrome patients who also have type 2 diabetes or glucose intolerance and are not surgical candidates.

Beyond Korlym, Corcept’s pipeline includes relacorilant (Phase III for hypercortisolism and in combination with nab-paclitaxel for platinum-resistant ovarian cancer), a Phase 1b program targeting adrenal cancer and cortisol excess, a Phase II trial for prostate cancer, dazucorilant (Phase II for amyotrophic lateral sclerosis), and miricorilant (Phase IIb for metabolic-dysfunction-associated steatohepatitis).

As of the latest 2024 filing, the company generated roughly $115 million in annual revenue, with ~ $260 million of cash and equivalents, giving it a runway of about 18 months without additional financing. The Cushing’s syndrome market is estimated at $1.5 billion globally, and glucocorticoid-receptor antagonists are a niche but growing segment within the broader endocrine-therapeutics space, which is being driven by an aging population and increasing prevalence of metabolic disorders.

Given Corcept’s reliance on a single commercial product and the high clinical-trial attrition risk inherent in its diversified pipeline, investors should closely monitor upcoming Phase III readouts for relacorilant and any FDA actions on Korlym’s labeling, as these events could materially shift the company’s cash-flow outlook.

For a deeper quantitative view, you might explore ValueRay’s analyst toolkit, which aggregates recent earnings and pipeline milestones.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (105.2m TTM) > 0 and > 6% of Revenue (6% = 44.5m TTM)

FCFTA 0.20 (>2.0%) and ΔFCFTA 1.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 49.77% (prev 54.21%; Δ -4.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.20 (>3.0%) and CFO 162.8m > Net Income 105.2m (YES >=105%, WARN >=100%)

Net Debt (-118.8m) to EBITDA (72.5m) ratio: -1.64 <= 3.0 (WARN <= 3.5)

Current Ratio 3.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (119.4m) change vs 12m ago 5.03% (target <= -2.0% for YES)

Gross Margin 98.19% (prev 98.44%; Δ -0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 92.19% (prev 80.15%; Δ 12.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3.94 (EBITDA TTM 72.5m / Interest Expense TTM -17.9m) >= 6 (WARN >= 3)

Altman Z'' 9.38

(A) 0.45 = (Total Current Assets 541.1m - Total Current Liabilities 172.3m) / Total Assets 823.6m

(B) 0.75 = Retained Earnings (Balance) 619.1m / Total Assets 823.6m

(D) 3.24 = Book Value of Equity 621.6m / Total Liabilities 191.7m

Total Rating: 9.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 67.13

1. Piotroski 5.50pt

2. FCF Yield 4.50%

3. FCF Margin 21.93%

4. Debt/Equity 0.01

5. Debt/Ebitda -1.64

6. ROIC - WACC (= -3.08)%

7. RoE 15.99%

8. Rev. Trend 96.63%

9. EPS Trend -16.50%

What is the price of CORT shares?

As of January 10, 2026, the stock is trading at USD 37.50 with a total of 1,612,825 shares traded.
Over the past week, the price has changed by -1.83%, over one month by -54.90%, over three months by -57.56% and over the past year by -24.77%.

Is CORT a buy, sell or hold?

Corcept Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CORT.

Strong Buy: 2
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CORT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	91	142.7%
Analysts Target Price	91	142.7%
ValueRay Target Price	40.9	9.1%

CORT Fundamental Data Overview January 05, 2026

P/E Trailing = 43.908
P/E Forward = 38.0228
P/S = 5.4309
P/B = 6.3589
P/EG = 0.61
Beta = 0.195
Revenue TTM = 741.2m USD
EBIT TTM = 70.6m USD
EBITDA TTM = 72.5m USD
Long Term Debt = 6.36m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.05m USD (from shortTermDebt, last quarter)
Debt = 6.36m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -118.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.61b USD (4.03b + Debt 6.36m - CCE 421.7m)
Interest Coverage Ratio = -3.94 (Ebit TTM 70.6m / Interest Expense TTM -17.9m)
EV/FCF = 22.21x (Enterprise Value 3.61b / FCF TTM 162.6m)
FCF Yield = 4.50% (FCF TTM 162.6m / Enterprise Value 3.61b)
FCF Margin = 21.93% (FCF TTM 162.6m / Revenue TTM 741.2m)
Net Margin = 14.19% (Net Income TTM 105.2m / Revenue TTM 741.2m)
Gross Margin = 98.19% ((Revenue TTM 741.2m - Cost of Revenue TTM 13.4m) / Revenue TTM)
Gross Margin QoQ = 97.79% (prev 98.23%)
Tobins Q-Ratio = 4.38 (Enterprise Value 3.61b / Total Assets 823.6m)
Interest Expense / Debt = 56.32% (Interest Expense 3.58m / Debt 6.36m)
Taxrate = 29.03% (4.42m / 15.2m)
NOPAT = 50.1m (EBIT 70.6m * (1 - 29.03%))
Current Ratio = 3.14 (Total Current Assets 541.1m / Total Current Liabilities 172.3m)
Debt / Equity = 0.01 (Debt 6.36m / totalStockholderEquity, last quarter 631.9m)
Debt / EBITDA = -1.64 (Net Debt -118.8m / EBITDA 72.5m)
Debt / FCF = -0.73 (Net Debt -118.8m / FCF TTM 162.6m)
Total Stockholder Equity = 657.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.08% (Net Income 105.2m / Total Assets 823.6m)
RoE = 15.99% (Net Income TTM 105.2m / Total Stockholder Equity 657.6m)
RoCE = 10.63% (EBIT 70.6m / Capital Employed (Equity 657.6m + L.T.Debt 6.36m))
RoIC = 7.62% (NOPAT 50.1m / Invested Capital 657.6m)
WACC = 10.70% (E(4.03b)/V(4.03b) * Re(10.72%) + (debt cost/tax rate unavailable))
Discount Rate = 10.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.79%
[DCF Debug] Terminal Value 70.29% ; FCFF base≈154.6m ; Y1≈167.2m ; Y5≈207.2m
Fair Price DCF = 23.36 (EV 2.34b - Net Debt -118.8m = Equity 2.46b / Shares 105.2m; r=10.70% [WACC]; 5y FCF grow 9.27% → 2.90% )
EPS Correlation: -16.50 | EPS CAGR: -44.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.63 | Revenue CAGR: 21.90% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.05 | Chg30d=+0.012 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.69 | Chg30d=-0.540 | Revisions Net=+1 | Growth EPS=-20.4% | Growth Revenue=+30.2%

Additional Sources for CORT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle